As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...

New research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

A recent study reveals that weight-loss medications such as Ozempic may reduce the risk of obesity-related cancers, including ...

GLP-1 receptor agonists may aid smoking cessation by curbing cravings and mitigating weight gain, which often are impediments in quitting, according to a presentation at the American Psychiatric ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more ...

GLP-1 RAs are great medications to help with weight loss and are particularly effective in decreasing “food noise” and the ...

“Our study found a similar incidence of obesity-related cancer among patients treated with first-generation glucagon-like peptide-1 receptor ... do not yet fully understand how GLP-1s work ...